Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2

Yusaku Akashi, Yoshihiko Kiyasu, Yuto Takeuchi, Daisuke Kato, Miwa Kuwahara, Shino Muramatsu, Atsuo Ueda, Shigeyuki Notake, Koji Nakamura, Hiroichi Ishikawa, Hiromichi Suzuki
doi: https://doi.org/10.1101/2021.06.09.21258157
Yusaku Akashi
1Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital, 1-3-1 Amakubo Tsukuba, Ibaraki 3058558, Japan
2Akashi Internal Medicine Clinic, 3-1-63 Asahigaoka, Kashiwara, Osaka 5820026, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yusaku-akashi@umin.ac.jp
Yoshihiko Kiyasu
1Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital, 1-3-1 Amakubo Tsukuba, Ibaraki 3058558, Japan
3Department of Infectious Diseases, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuto Takeuchi
1Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital, 1-3-1 Amakubo Tsukuba, Ibaraki 3058558, Japan
3Department of Infectious Diseases, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daisuke Kato
4Research & Development Division, Reagent R&D Department, Gosen site, Denka Co., Ltd., 1-2-2 Minamihoncho, Gosen-shi, Niigata 9591695, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miwa Kuwahara
4Research & Development Division, Reagent R&D Department, Gosen site, Denka Co., Ltd., 1-2-2 Minamihoncho, Gosen-shi, Niigata 9591695, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shino Muramatsu
4Research & Development Division, Reagent R&D Department, Gosen site, Denka Co., Ltd., 1-2-2 Minamihoncho, Gosen-shi, Niigata 9591695, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsuo Ueda
5Department of Clinical Laboratory, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki 3058558, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigeyuki Notake
5Department of Clinical Laboratory, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki 3058558, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koji Nakamura
5Department of Clinical Laboratory, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki 3058558, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroichi Ishikawa
6Department of Respiratory Medicine, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki 3058558, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiromichi Suzuki
1Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital, 1-3-1 Amakubo Tsukuba, Ibaraki 3058558, Japan
3Department of Infectious Diseases, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan
7Department of Infectious Diseases, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Antigen tests for severe acute respiratory coronavirus 2 sometimes show positive lines earlier than their specified read time, although the implication of getting the results at earlier time is not well understood. This study aimed to evaluate the clinical utility of an antigen test by evaluating the time period to get positive results and by comparing the test sensitivity with that of a digital immunoassay (DIA) test.

We prospectively collected additional nasopharyngeal samples from patients who had already tested positive for SARS-CoV-2 by reverse transcription PCR. The additional swab was used for an antigen test, QuickNavi™-COVID19 Ag, and the time periods to get positive results were measured. The sensitivity of QuickNavi™-COVID19 Ag was also compared with that of a DIA.

In 84 of 96 (87.5%) analyzed cases, the results of QuickNavi™-COVID19 Ag were positive. The time to obtain positive results was 15.0 seconds in median (inter quartile range: 12.0-33.3, range 11-736), and was extended in samples with higher cycle thresholds (Ct) (p<0.001). Positive lines appeared within a minute in 85.7% of cases and within 5 minutes in 96.4%. The sensitivities of QuickNavi™-COVID19 Ag and the DIA were 87.5% (95% confident interval [CI]: 79.2%-93.4%) and 88.6% (95%CI: 75.4%- 96.2%), respectively. Their results were concordant in 90.9% of cases, with discrepancies present only in cases with Ct values >32.

QuickNavi™-COVID19 Ag immediately showed positive results in most cases, and the time to a positive reaction may have indicated the viral load. In addition, the sensitivity of the test was comparable to the DIA.

Competing Interest Statement

Denka Co., Ltd., and Mizuho Medy Co., Ltd. provided test kits free of charge. Regarding this study, Hiromichi Suzuki received lecture fees from Denka Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., and a consultation fee from Mizuho Medy Co., Ltd. Daisuke Kato, Miwa Kuwahara, and Shino Muramatsu are employed by Denka Co., Ltd., the developer of QuickNavi™-COVID19 Ag.

Funding Statement

Denka Co., Ltd., and Mizuho Medy Co., Ltd. provided test kits free of charge. Regarding this study, Hiromichi Suzuki received lecture fees from Denka Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., and a consultation fee from Mizuho Medy Co., Ltd.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The ethics committee of Tsukuba Medical Center Hospital (TMCH) approved the present study (approval number: 2020-033).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • E-mail addresses of each author: Yusaku Akashi, yusaku-akashi{at}umin.ac.jp; Yoshihiko Kiyasu, kiyasu-tuk{at}umin.ac.jp; Yuto Takeuchi, yuto-takeuchi{at}umin.ac.jp; Daisuke Kato, daisuke-kato{at}denka.co.jp; Miwa Kuwahara, miwa-kuwahara{at}denka.co.jp; Shino Muramatshu, shino-muramatsu{at}denka.co.jp; Atsuo Ueda, atsuo.ueda06090727{at}outlook.jp; Shigeyuki Notake, notake{at}tmch.or.jp; Koji Nakamura, koji-nakamura{at}tmch.or.jp; Hiroichi Ishikawa, hishikawa{at}tmch.or.jp; Hiromichi Suzuki, hsuzuki{at}md.tsukuba.ac.jp

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 13, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2
Yusaku Akashi, Yoshihiko Kiyasu, Yuto Takeuchi, Daisuke Kato, Miwa Kuwahara, Shino Muramatsu, Atsuo Ueda, Shigeyuki Notake, Koji Nakamura, Hiroichi Ishikawa, Hiromichi Suzuki
medRxiv 2021.06.09.21258157; doi: https://doi.org/10.1101/2021.06.09.21258157
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2
Yusaku Akashi, Yoshihiko Kiyasu, Yuto Takeuchi, Daisuke Kato, Miwa Kuwahara, Shino Muramatsu, Atsuo Ueda, Shigeyuki Notake, Koji Nakamura, Hiroichi Ishikawa, Hiromichi Suzuki
medRxiv 2021.06.09.21258157; doi: https://doi.org/10.1101/2021.06.09.21258157

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (577)
  • Anesthesia (139)
  • Cardiovascular Medicine (1942)
  • Dentistry and Oral Medicine (252)
  • Dermatology (183)
  • Emergency Medicine (331)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (697)
  • Epidemiology (11086)
  • Forensic Medicine (8)
  • Gastroenterology (619)
  • Genetic and Genomic Medicine (3156)
  • Geriatric Medicine (307)
  • Health Economics (560)
  • Health Informatics (2037)
  • Health Policy (861)
  • Health Systems and Quality Improvement (781)
  • Hematology (309)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12702)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2977)
  • Nursing (162)
  • Nutrition (461)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1548)
  • Ophthalmology (474)
  • Orthopedics (185)
  • Otolaryngology (265)
  • Pain Medicine (201)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (909)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (354)
  • Psychiatry and Clinical Psychology (2774)
  • Public and Global Health (5583)
  • Radiology and Imaging (1090)
  • Rehabilitation Medicine and Physical Therapy (630)
  • Respiratory Medicine (755)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (287)
  • Surgery (342)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (131)